# A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

> **NCT05610657** · PHASE1 · COMPLETED · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Moderate Hepatic Impairment

## Interventions

- **DRUG:** Mitapivat

## Key facts

- **NCT ID:** NCT05610657
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2023-07-21
- **Final completion:** 2023-07-21
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610657, "A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05610657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*